We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-17.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.58B
AUM Growth
-$1.09B
Cap. Flow
+$290M
Cap. Flow %
6.34%
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$158M
2
NTRA icon
Natera
NTRA
+$78.7M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$62.7M
4
ANTX icon
AN2 Therapeutics
ANTX
+$55.6M
5
CTKB icon
Cytek Biosciences
CTKB
+$51M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$125M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$61.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$54.2M
4
CCCC icon
C4 Therapeutics
CCCC
+$44.4M
5
TGTX icon
TG Therapeutics
TGTX
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 98.82%
2 Financials 0.96%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
51
Edgewise Therapeutics
EWTX
$4.74B
$25.4M 0.55%
2,613,623
– –
STSA
52
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$22.5M 0.49%
5,914,252
– –
CNTB
53
Connect Biopharma Holdings
CNTB
$73.7M
$21.1M 0.46%
6,991,003
– –
HOWL icon
54
Werewolf Therapeutics
HOWL
$47.6M
$18.9M 0.41%
4,291,881
– –
ETNB
55
DELISTED
89bio
ETNB
$18.7M 0.41%
4,965,769
– –
TNGX icon
56
Tango Therapeutics
TNGX
$4.03B
$17.1M 0.37%
2,250,000
– –
RLAY icon
57
Relay Therapeutics
RLAY
$4.16B
$16.4M 0.36%
549,055
– –
KDNY
58
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$16.4M 0.36%
1,000,000
– –
SYBX
59
DELISTED
Synlogic
SYBX
$16M 0.35%
444,444
– –
WVE icon
60
Wave Life Sciences
WVE
$879M
$15.6M 0.34%
7,775,207
– –
SCPH
61
DELISTED
scPharmaceuticals
SCPH
$15.1M 0.33%
2,658,583
-33,187
-1% -$163K
KALA icon
62
KALA BIO
KALA
$9.82M
$15M 0.33%
4,354
– –
SLDB icon
63
Solid Biosciences
SLDB
$897M
$14.8M 0.32%
824,525
– –
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
$14.7M 0.32%
5,014,687
– –
DALS
65
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$14.6M 0.32%
1,500,000
– –
MIST icon
66
Milestone Pharmaceuticals
MIST
$115M
$14.4M 0.31%
2,246,503
– –
XLO icon
67
Xilio Therapeutics
XLO
$59.4M
$14.2M 0.31%
143,016
– –
LENZ
68
LENZ Therapeutics
LENZ
$133M
$13.8M 0.3%
385,481
– –
OTIC
69
DELISTED
Otonomy, Inc.
OTIC
$13.4M 0.29%
5,600,000
– –
CYT
70
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$12.6M 0.28%
3,350,506
– –
BLSA
71
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$12.3M 0.27%
1,250,000
– –
IPSC icon
72
Century Therapeutics
IPSC
$359M
$11.5M 0.25%
914,094
– –
MORF
73
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.2M 0.24%
+278,874
New +$11.7M
AKUS
74
DELISTED
Akouos Inc
AKUS
$10.8M 0.24%
2,281,249
– –
CNCE
75
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$10.2M 0.22%
3,033,603
– –
1 2
3
4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.

  • RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
  • RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
  • RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
  • RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
  • RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
  • RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
  • RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.